Vicarious Surgical (RBOT) Capital Leases (2022 - 2023)
Vicarious Surgical (RBOT) reported Capital Leases of $14.3 million for Q2 2023, down 6.32% year-over-year from $15.3 million in Q2 2022, and down 1.8% quarter-over-quarter from $14.6 million in Q1 2023.
Vicarious Surgical (RBOT) Capital Leases (2022 - 2023) Analysis & Trends
Vicarious Surgical (RBOT) has 2 years of Capital Leases data on file, last reported at $14.3 million in Q2 2023.
- Capital Leases for Q2 2023 came in at $14.3 million, down 6.32% year-over-year; the trailing twelve-month figure through Jun 2023 was $14.3 million (down 6.32% YoY), and the FY2022 annual result was $14.8 million, changed N/A from the prior year.
- Capital Leases slipped to $14.3 million in Q2 2023 per RBOT's latest filing, from $14.6 million in the prior quarter.
- Over five years, Capital Leases peaked at $15.5 million in Q1 2022 and troughed at $14.3 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn |
| 10 | Vicarious Surgical | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 14.33 Mn |
| Mar 31, 2023 | 14.59 Mn |
| Dec 31, 2022 | 14.83 Mn |
| Sep 30, 2022 | 15.07 Mn |
| Jun 30, 2022 | 15.30 Mn |
| Mar 31, 2022 | 15.52 Mn |